Melinta Therapeutics, Inc.
Officers & Directors
Melinta Therapeutics, Inc. is a biopharmaceutical company that develops and markets antibiotics to treat serious infectious diseases.
Their current Board of Directors includes:
Charles M. Baum, MD, MBA - Chairman of the Board
Dr. Baum brings over 25 years of experience in the healthcare industry to his role as Chairman of the Board. He is also the CEO of Mirati Therapeutics, a clinical-stage biopharmaceutical company focused on developing cancer treatments.
David N. Gill, PhD - Director
With over 25 years of experience in the pharmaceutical and biotechnology industries, Dr. Gill serves as a director for Melinta Therapeutics. He is also a member of the board of directors for several other biotechnology and life sciences companies.
Jennifer Sanfilippo - Director
Ms. Sanfilippo has over 20 years of experience in the biotechnology and pharmaceutical industries. She is also a member of the Board of Directors for several other biotechnology and life sciences companies.
John H. Johnson - Director
Mr. Johnson is the CEO and Executive Chairman of the board for Dicerna Pharmaceuticals, a clinical-stage biopharmaceutical company. He has over 25 years of experience in the life sciences industry, including as the former CEO of Savient Pharmaceuticals and ImClone Systems.
The CEO and executive team leading the company are not able to be determined without more specific information as they may have changed since the last available report.
Melinta Therapeutics, Inc. currently has 253 employees.
|
